Research Papers:

Low fT3 is associated with diminished health-related quality of life in patients with acute coronary syndrome treated with drug-eluting stent: a longitudinal observational study

Chao Xue, Ling Bian, Yu Shui Xie, Zhao Fang Yin, Zuo Jun Xu, Qi Zhi Chen, Hui Li Zhang, Yu Qi Fan, Run Du and Chang Qian Wang _

PDF  |  HTML  |  How to cite

Oncotarget. 2017; 8:94580-94590. https://doi.org/10.18632/oncotarget.21811

Metrics: PDF 1801 views  |   HTML 2552 views  |   ?  


Chao Xue1,*, Ling Bian1,*, Yu Shui Xie1, Zhao Fang Yin1, Zuo Jun Xu1, Qi Zhi Chen1, Hui Li Zhang1, Yu Qi Fan1, Run Du2 and Chang Qian Wang1

1Department of Cardiology, Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200011, People’s Republic of China

2Department of Cardiology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, People’s Republic of China

*These authors have contributed equally to this work

Correspondence to:

Chang Qian Wang, email: [email protected]

Run Du, email: [email protected]

Keywords: health-related quality of life, free triiodothyronine, drug-eluting stent, acute coronary syndrome

Received: May 31, 2017     Accepted: September 20, 2017     Published: October 10, 2017


Acute coronary syndrome (ACS) patients with low triiodothyronine (T3) syndrome characterized by low free T3 (fT3) levels with normal thyroxine (T4) and thyroid-stimulating hormone (TSH) have a higher rate of death. The impact of fT3 on Health related quality of life (HRQOL) in patients with ACS is still unknown. 528 ACS patients treated with drug-eluting stent (DES) were included in this prospective, observational study. Patients were classified into low fT3 group (n=126) and normal fT3 group (n=402) according to serum fT3 level. Every patient was prospectively interviewed at baseline and 1 year following percutaneous coronary intervention (PCI). HRQOL was assessed with the use of the Medical Outcomes Study 36-Item Short-Form Health Survey (SF-36). Low fT3 patients had poorer HRQOL than normal fT3 patients both at baseline and 1-year follow-up (all p<0.05). During 1-year follow-up, HRQOL scores for all patients were significantly higher than baseline. Low fT3 patients had lesser gains in physical functioning, bodily pain, general health, vitality, social functioning and role emotional (all p<0.05). Generally, low fT3 patients demonstrated less improvement in Physical Component Score (PCS) (p=0.008) and Mental Component Score (MCS) (p=0.001). The percentage of patients reaching MCID for PCS and MCS was lower in low fT3 group than that in normal fT3 group (p<0.001). Multivariate linear regression analyses showed that low level of fT3 was an independent risk factor for PCS and MCS improvements. In conclusion, a low fT3 level is a predictor of worse HRQOL improvement in ACS patients treated with DES.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 21811